Cardinal Health, Inc. is rated a Buy with a $239 fair value, driven by specialty growth in autoimmune, urology & oncology.

Adjusted EBITDA (Q4): Adjusted EBITDA loss of $316,000 for Q4 FY2025, substantially narrowed from a $1.7 million adjusted ...

Fubo TV (NYSE:FUBO) hits a pivotal milestone with its first positive adjusted EBITDA, beating earnings expectations despite a ...

Fox Corporation said profit rose in its fiscal fourth quarter thanks in part to advertiser interest in Fox News and Tubi ...

Micron Technology raised its fourth-quarter revenue and profit forecast on Monday. The move comes as demand for its memory ...

Cardinal Health, Inc. (NYSE:CAH) will release earnings results for the fourth quarter before the opening bell on Tuesday, Aug ...

A small investment today could turn into something big tomorrow. Four hidden altcoins are attracting attention for their ...

Bitcoin (CRYPTO: BTC) and Ethereum (CRYPTO: ETH) could see a strong end to the year, according to fresh technical analysis by ...

Micron Technology shares rise after raising Q4 2025 outlook on strong DRAM pricing, product launches, and robust AI memory demand.

Intelligent Bio forecasts 16% revenue growth for Q4 2025 and strengthens FDA filing with new data as it expands global reach ...

Shares of S uper Micro Computer, Inc. SMCI -19.1% Get Free Report fell sharply in pre-market trading after the company ...

As Q4 2025 approaches, investor interest is heating up around Ethereum alternatives, especially Solana (SOL) and Aptos (APT).